Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
GNLX Genelux	$2.78 +0.4%	$2.67	$1.60 ▼ $5.89	$104.53M	-0.49	190,601 shs	49,300 shs
KMDA Kamada	$7.95 +9.5%	$6.80	$4.83 ▼ $9.16	$417.49M	0.94	95,973 shs	349,033 shs
NGNE Neurogene	$17.20 -0.1%	$16.89	$6.88 ▼ $74.49	$245.59M	1.57	250,366 shs	238,961 shs
SAGE Sage Therapeutics	$9.22 -0.9%	$7.27	$4.62 ▼ $13.47	$582.37M	0.18	1.28 million shs	1.29 million shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
GNLX Genelux	-6.73%	-14.24%	+7.36%	-18.53%	+34.47%
KMDA Kamada	+0.83%	+1.54%	+9.50%	+2.54%	+51.88%
NGNE Neurogene	-3.04%	-9.23%	-0.35%	+21.27%	-44.47%
SAGE Sage Therapeutics	0.00%	+2.54%	+42.42%	+9.03%	-16.44%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
GNLX Genelux	0.7318 of 5 stars	3.6	0.0	0.0	0.0	0.0	0.0
KMDA Kamada	3.8076 of 5 stars	3.4	3.0	0.0	2.3	1.7	3.1
NGNE Neurogene	3.5636 of 5 stars	4.4	3.0	0.0	1.9	1.7	1.3
SAGE Sage Therapeutics	3.0011 of 5 stars	2.0	1.0	4.0	2.9	1.7	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
GNLX Genelux	3.20	Buy	$17.75	538.49% Upside
KMDA Kamada	2.75	Moderate Buy	$14.67	84.49% Upside
NGNE Neurogene	2.75	Moderate Buy	$46.17	168.41% Upside
SAGE Sage Therapeutics	2.00	Hold	$8.93	-3.11% Downside

Current Analyst Ratings Breakdown

Latest GNLX, KMDA, NGNE, and SAGE Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
6/20/2025	SAGE Sage Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
6/17/2025	NGNE Neurogene	Craig Hallum Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$50.00
6/17/2025	SAGE Sage Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold	$9.00 ➝ $8.50
6/17/2025	SAGE Sage Therapeutics	Truist Financial Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Hold ➝ Hold	$8.00 ➝ $9.00
6/17/2025	SAGE Sage Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Neutral ➝ Neutral	$12.00
6/17/2025	SAGE Sage Therapeutics	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Hold ➝ Hold	$8.00 ➝ $8.50
6/16/2025	SAGE Sage Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
6/12/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform ➝ Outperform	$22.00 ➝ $26.00
5/20/2025	NGNE Neurogene	BMO Capital Markets Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $22.00
5/16/2025	NGNE Neurogene	Baird R W Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	NGNE Neurogene	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Outperform ➝ Neutral	$38.00 ➝ $24.00

(Data available from 6/24/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
GNLX Genelux	$10K	10,491.72	N/A	N/A	$0.76 per share	3.66
KMDA Kamada	$160.95M	2.84	$0.54 per share	14.77	$4.51 per share	1.76
NGNE Neurogene	$930K	263.73	N/A	N/A	$20.89 per share	0.82
SAGE Sage Therapeutics	$41.24M	14.00	N/A	N/A	$7.60 per share	1.21

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
GNLX Genelux	-$29.87M	-$0.88	0.00	N/A	N/A	N/A	-93.04%	-74.17%	8/13/2025 (Estimated)
KMDA Kamada	$14.46M	$0.29	25.03	24.84	0.88	9.60%	6.31%	4.43%	8/13/2025 (Estimated)
NGNE Neurogene	-$75.14M	-$4.35	0.00	N/A	N/A	N/A	-36.16%	-32.51%	8/8/2025 (Estimated)
SAGE Sage Therapeutics	-$400.67M	-$5.80	0.00	N/A	N/A	-747.63%	-68.99%	-60.67%	7/30/2025 (Estimated)

Latest GNLX, KMDA, NGNE, and SAGE Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	KMDA Kamada	$0.07	$0.07	N/A	$0.07	$154.06 million	$44.02 million
5/9/2025	Q1 2025	NGNE Neurogene	-$1.05	-$1.08	-$0.03	-$1.08	N/A	N/A
5/8/2025	Q1 2025	GNLX Genelux	-$0.24	-$0.21	+$0.03	-$0.21	N/A	N/A
4/29/2025	Q1 2025	SAGE Sage Therapeutics	-$0.99	-$1.01	-$0.02	-$1.01	$14.12 million	$14.06 million
3/28/2025	Q4 2024	GNLX Genelux	-$0.17	-$0.26	-$0.09	-$0.26	N/A	N/A
3/24/2025	Q4 2024	NGNE Neurogene	-$1.04	-$0.99	+$0.05	-$0.99	N/A	$0.93 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
GNLX Genelux	N/A	N/A	N/A	N/A	N/A
KMDA Kamada	N/A	N/A	N/A	N/A	N/A
NGNE Neurogene	N/A	N/A	N/A	N/A	N/A
SAGE Sage Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
GNLX Genelux	N/A	4.67	4.67
KMDA Kamada	N/A	3.30	1.93
NGNE Neurogene	N/A	21.03	21.03
SAGE Sage Therapeutics	N/A	9.13	9.13

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
GNLX Genelux	37.33%
KMDA Kamada	20.38%
NGNE Neurogene	52.37%
SAGE Sage Therapeutics	99.22%

Insider Ownership

Company	Insider Ownership
GNLX Genelux	9.30%
KMDA Kamada	36.10%
NGNE Neurogene	9.92%
SAGE Sage Therapeutics	5.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
GNLX Genelux	10	37.74 million	34.23 million	Not Optionable
KMDA Kamada	360	57.51 million	36.75 million	Optionable
NGNE Neurogene	90	14.26 million	12.85 million	Optionable
SAGE Sage Therapeutics	690	62.62 million	59.18 million	Optionable

GNLX, KMDA, NGNE, and SAGE Headlines

Recent News About These Companies

Sage Therapeutics Stock: JPMorgan Sees 8% Downside After Supernus Buyout Terms

June 23 at 8:36 AM | msn.com

Phathom Pharmaceuticals Appoints Anne Marie Cook as Chief Legal Officer and Corporate Secretary

June 23 at 7:59 AM | globenewswire.com

Sage Therapeutics price target lowered to $8.50 from $11 at JPMorgan

June 22 at 8:25 PM | msn.com

Robert W. Baird Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 21 at 1:57 AM | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Given New $9.00 Price Target at Robert W. Baird

June 20, 2025 | marketbeat.com

Rx Rundown: Sanofi, Processa Pharmaceuticals, Eli Lilly and more

June 20, 2025 | mmm-online.com

Sage Therapeutics (NASDAQ:SAGE) Rating Lowered to Hold at Piper Sandler

June 19, 2025 | americanbankingnews.com

Truist Financial Raises Sage Therapeutics (NASDAQ:SAGE) Price Target to $9.00

June 19, 2025 | americanbankingnews.com

Sage Therapeutics (NASDAQ:SAGE) Receives Neutral Rating from HC Wainwright

June 19, 2025 | americanbankingnews.com

SAGE THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Sage Therapeutics, Inc. - SAGE

June 18, 2025 | businesswire.com

Another Gene Therapy Death; Biopharma M&A Picks Up; a Vaccine Board of Vaccine Skeptics

June 18, 2025 | biospace.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $8.50 at Canaccord Genuity Group

June 18, 2025 | americanbankingnews.com

SAGE to be Acquired by Supernus Pharmaceuticals in $795 Million Deal

June 17, 2025 | zacks.com

Sage Therapeutics (SAGE) Soars 35.4%: Is Further Upside Left in the Stock?

June 17, 2025 | zacks.com

Sage Therapeutics (NASDAQ:SAGE) Earns Neutral Rating from Piper Sandler

June 17, 2025 | marketbeat.com

Sage Therapeutics (NASDAQ:SAGE) Price Target Raised to $9.00

June 17, 2025 | marketbeat.com

HC Wainwright Reaffirms "Neutral" Rating for Sage Therapeutics (NASDAQ:SAGE)

June 17, 2025 | marketbeat.com

Bronstein, Gewirtz & Grossman, LLC Is Investigating Sage Therapeutics, Inc. (SAGE) And Encourages Stockholders to Connect

June 17, 2025 | accessnewswire.com

Sage Therapeutics (NASDAQ:SAGE) Given New $8.50 Price Target at Canaccord Genuity Group

June 17, 2025 | marketbeat.com

After rebuffing Biogen, Sage pairs off with Supernus

June 17, 2025 | pharmaphorum.com

Supernus makes depression drug play with $795m Sage buyout

June 17, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

GNLX, KMDA, NGNE, and SAGE Company Descriptions

Genelux NASDAQ:GNLX

$2.78 +0.01 (+0.36%)

Closing price 04:00 PM Eastern

Extended Trading

$2.79 +0.01 (+0.36%)

As of 04:04 PM Eastern

Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing next-generation oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec, a proprietary modified strain of the vaccinia virus for the treatment of ovarian cancer and non-small cell lung cancer. The company is also developing V2ACT Immunotherapy for treating pancreatic cancer. Genelux Corporation has a licensing agreement with ELIAS Animal Health, LLC for V-VET1, a clinical stage animal health product candidate. The company was incorporated in 2001 and is headquartered in Westlake Village, California.

Kamada NASDAQ:KMDA

$7.95 +0.69 (+9.50%)

Closing price 04:00 PM Eastern

Extended Trading

$7.99 +0.04 (+0.49%)

As of 07:31 PM Eastern

Kamada Ltd. manufactures and sells plasma-derived protein therapeutics. Its commercial products include KAMRAB/KEDRAB for treating prophylaxis of rabies; CYTOGAM for Prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; KAMRHO (D) IV for immune thermobocytopunic purpura; and Echis coloratus and Vipera palaestinae Antiserum for the treatment of snake bite. The company also distributes imported drug products in Israel, including BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; TRIMBOW for chronic obstructive pulmonary disease; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN and RUPAFIN ORAL SOLUTION for allergic rhinitis and Urticaria; SINTREDIUS for rheumatoid arthritis, systemic lupus erythematosus, and mild-moderate juvenile dermatomyositis; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for CMV virus; RUCONEST for angioedema attack; HEPARIN SODIUM INJECTION for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN and ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. In addition, it distributes COAGADEX for hereditary factor X deficiency; IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; ELIGARD for prostate cancer; and BEVACIZUMAB KAMADA for various cancers. The company was incorporated in 1990 and is headquartered in Rehovot, Israel.

Neurogene NASDAQ:NGNE

$17.20 -0.02 (-0.12%)

Closing price 04:00 PM Eastern

Extended Trading

$17.20 0.00 (0.00%)

As of 07:56 PM Eastern

Neurogene Inc., a biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 which is packaged in an adeno-associated virus 9 that is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of North Carolina, the University of Edinburgh, Virovek, Inc., and Sigma-Aldrich Co. LLC. The company is headquartered in New York, New York.

Sage Therapeutics NASDAQ:SAGE

$9.22 -0.08 (-0.86%)

Closing price 04:00 PM Eastern

Extended Trading

$9.20 -0.02 (-0.26%)

As of 07:51 PM Eastern

Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes brain health medicines. Its product candidates include ZULRESSO, a CIV injection for the treatment of postpartum depression (PPD) in adults; and ZURZUVAE, a neuroactive steroid, a positive allosteric modulator of GABAA receptors, targeting both synaptic and extrasynaptic GABAA receptors, for the treatment of postpartum depression. Its product pipeline also comprises SAGE-324, a compound that is in Phase II clinical trial to treat essential tremors, as well as has completed Phase I clinical trial for epilepsy and Parkinson's diseases; and SAGE-718, an oxysterol-based positive allosteric modulator of the NMDA receptor, which is in Phase II clinical trial for the treatment of depression, Huntington's disease, Parkinson's diseases, Alzheimer's disease, attention deficit hyperactivity disorder, schizophrenia, and neuropathic pain. The company has a strategic collaboration with Shionogi & Co., Ltd. for the development and commercialization of zuranolone in Japan, Taiwan, and South Korea; and a collaboration and license agreement with Biogen MA Inc. to jointly develop and commercialize SAGE-217 and SAGE-324 products. The company was formerly known as Sterogen Biopharma, Inc. and changed its name to Sage Therapeutics, Inc. in September 2011. Sage Therapeutics, Inc. was incorporated in 2010 and is headquartered in Cambridge, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time